TITLE

Patheon's CEO Speaks

AUTHOR(S)
Roth, Gil Y.
PUB. DATE
May 2012
SOURCE
Contract Pharma;May2012, Vol. 14 Issue 4, p104
SOURCE TYPE
Trade Publication
DOC. TYPE
Interview
ABSTRACT
An interview with Jim Mullen, Patheon Inc.'s chief executive officer (CEO), is presented. He discusses the economic trends on the outsourcing processes at the pharmaceutical industry. He also tackles strategic partnerships of business enterprises at the industry and notes his administration at Biogen Idec.
ACCESSION #
74763005

 

Related Articles

  • Nanotechnology Will Deliver Medicines Where They Need to Be. Weeks, Katie // San Diego Business Journal;11/20/2006, Vol. 27 Issue 47, p4 

    The article reports on the contribution and achievement of Bill Rastetter in the field of biotechnology industry in the U.S. Rastetter was responsible for the merger of Biogen Idec Inc., which is now the third largest biotechnology company in the world. He was the chairman of the board at Biogen...

  • Biogen Idec set on developing pipeline of drugs.  // PharmaWatch: Biotechnology;February 2004, Vol. 3 Issue 2, p14 

    Reports that Biogen Idec Inc. CEO Jim Mullen has dismissed claims that its recent merger was set upon achieving economies of scale. Aim of the company to develop a pipeline of drugs previously unobtainable to each party; Potentials of the company to develop molecule drugs; Amount of sales...

  • Industry Audit Winner Outtakes: Blockbusters, Indoor Golf, and the Velvet Underground.  // Pharmaceutical Executive;Sep2011, Vol. 31 Issue 9, p114 

    The article presents information on pharmaceutical companies including Novo Nordisk, Gilead Sciences Inc., Celgene, Biogen Idec Inc., and AstraZeneca PLC. Details on their blockbusters, chief executive officers (CEOs) since 2001, dividends in 2010, headquarter (HQ) local flavor, and employee...

  • Newsmakers: Peter Bigelow. Roth, Gil Y. // Contract Pharma;Jan/Feb2011, Vol. 13 Issue 1, p48 

    An interview with Peter Bigelow, interim chief executive officer (CEO) of Patheon Inc., is presented. He discusses how the transition in their company was going and praises how the team supported him in his position as CEO. He mentions the importance of their strong Pharmaceutical Development...

  • Master supply agreement.  // Pharmaceutical Technology Europe;Mar2006, Vol. 18 Issue 3, p12 

    The article reports on pharmaceutical firm Merck & Co. Inc.'s supply agreement with contract manufacturing organization (CMO) Patheon Inc. Merck had a long-standing relationship with MOVA, a CMO bought by Patheon. Three initial projects will be given by Merck to Patheon, which will be spread...

  • Contract services.  // Pharmaceutical Technology;Mar2012, Vol. 36 Issue 3, p92 

    The article offers brief information on the contract development and manufacturing services offered by Patheon Inc. to the pharmaceutical industry.

  • Future Imperfect for Quintiles? Miller, Jim // Pharmaceutical Technology Europe;Mar2003 Supplement, Vol. 15, p11 

    Examines the operations of North American pharmaceutical contract services firms Quintiles Transnational Corp. and Patheon Inc. in 2002 and 2003. Quintiles' rejection of an offer by its founder and board chairman Dennis Gillings to buy back the firm from its shareholders; Quintiles' revenues...

  • LigoCyte, Biogen Partner On Inflammatory Diseases.  // Bioworld Week;9/24/2007, Vol. 15 Issue 39, p3 

    The article reports on the partnership between LigoCyte Pharmaceuticals Inc. and Biogen Idec Inc. to develop therapies to treat chronic inflammatory disease in the U.S. The firms will develop products that target CD103, a unique alphaEbeta7 integrin that has been implicated in the activation,...

  • Patheon to sell Carolina plant, growth projected for remaining plants. Thurston, Lawson D. // Caribbean Business;1/31/2008, Vol. 36 Issue 4, p40 

    The article reports on the outlook of Wesley P. Wheeler, the new CEO of Puerto Rican pharmaceutical firm Patheon, regarding the future of the company. Wheeler expects growth in their Manatí and Caugas operations because of their research and new drug development initiatives. He states that...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics